Brain cancer
Brain cancer is one of the most aggressive and difficult-to-treat malignancies. Moreover, in the almost 50 years since the start of the war on cancer, the prospects for people who develop brain cancer have improved much more slowly than those of individuals with other types of cancer. Despite a lack of progress in the clinic, research on this group of conditions is advancing steadily, and treatments with the potential to transform the field are on the horizon.
This Nature Outlook is editorially independent. It is produced with third party financial support. About this content.
This Nature Outlook is editorially independent, produced with financial support from a third party. About this content.
Nature is pleased to acknowledge the financial support of Novocure in producing this Outlook. The sponsor retains sole responsibility for the following message.
Novocure is a global oncology company developing a proprietary platform technology called Tumor Treating Fields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division.The science of Tumor Treating Fields may have the potential to treat a range of solid tumor cancers. Novocure’s commercialized product is approved for the treatment of adult patients with glioblastoma multiforme (GBM).
The company, which has operations in the US, Europe and Asia, began with a patient-forward approach that continues to drive our mission today. With over 15 years of research and many significant milestones reached, we have established ourselves as an innovator in oncology dedicated to improving the lives of cancer patients.
For additional information about the company, please visit www.novocure.com or follow us at www.twitter.com/novocure.
